Clinical Trial

Pharmaco-Neuroimaging Studies of Approach/Avoidance Behaviors and Post-Mortem Studies: Pharmacological Manipulation

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
The study will investigate whether a nociceptin receptor antagonist will normalize neural and behavioral processes of approach/avoidance decision-making in unmedicated individuals with major depressive disorder (MDD) and anxiety disorders. More specifically, the study aims to investigate dysregulation within (1) corticostriatal-midbrain circuitry and (2) nociceptin/orphanin FQ peptide and the nociceptin receptor (NOPR).
Protocol Amendment History 11 amendments
This ClinicalTrials.gov record has been amended 11 times since 2022-02-01; most recent amendment 2026-05-15.
Status change: Not Yet Recruiting → Recruiting 2025-10-17
Trial Details
NCT Number NCT05232032
Lead Sponsor Mclean Hospital
Collaborators: National Institute of Mental Health (NIMH), Massachusetts General Hospital, Massachusetts Institute of Technology, University of Washington, Brown University
Conditions Depressive Disorder, Major, Anxiety Disorder
Enrollment 112 participants
Start Date 2025-02-01
Primary Completion 2027-03-31 (estimated)
Study Completion 2027-03-31 (estimated)
Updated on ClinicalTrials.gov 2026-05-18